Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
The antibody was designed and developed at Abzena’s Cambridge, UK,
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated
